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INTRODUCTION
It has been almost four decades since the three endogenous
opioid peptide families, enkephalins, endorphins and
dynorphins, have been identified and characterized (1).
Pharmacological approaches have shown the existence of three
types of opioid peptide receptors µ (MOP), δ (DOP), and (KOP)
(2, 3). Although selectivity of the enkephalins for the δ-receptor
(4) and of dynorphins for the -receptor (5) was demonstrated, no
specific endogenous ligand had been attributed to the µ-receptor.
The pro-opiomelanocortin (POMC) product β-endorphin (6)
exhibited very good affinities for each type of opioid receptors,
without showing a genuine preference for any of them. About
two decades later two endogenous, potent, and selective opioid
peptides, named endomorphin-1 (Tyr-Pro-Trp-Phe-NH2) and
endomorphin-2 (Tyr-Pro-Phe-Phe-NH2), were isolated from
bovine brain (7). They produced antinociception in mice after
intracerebroventricular administration and displayed
extraordinarily high selectivity toward µ-opioid receptors in
radioreceptor binding assays. It was concluded therefore that
these peptides might be natural ligands for the µ-receptors.
Opioid receptors are coupled to heterotrimeric G-proteins
(8) and, upon ligand-activation, are known to inhibit adenylyl
cyclase (9). Accordingly, like other µ-receptor specific ligands,
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Endomorphins are natural amidated opioid tetrapeptides with the following structure: Tyr-Pro-Trp-Phe-NH2
(endomorphin-1), and Tyr-Pro-Phe-Phe-NH2 (endomorphin-2). Endomorphins interact selectively with the µ-opioid or
MOP receptors and exhibit nanomolar or sub-nanomolar receptor binding affinities, therefore they suggested to be
endogenous agonists for the µ-opioid receptors. Endomorphins mediate a number of characteristic opioid effects, such
as antinociception, however there are several physiological functions in which endomorphins appear to act in a fashion
that does not involve binding to and activation of the µ-opioid receptor. Our recent data indicate that a radiolabelled
[3H]endomorphin-1 with a specific radioactivity of 2.35 TBq/mmol - prepared by catalytic dehalogenation of the
diiodinated peptide precursor in the presence of tritium gas - is able to bind to a second, naloxone insensitive recognition
site in rat brain membranes. Binding heterogeneity, i.e., the presence of higher (Kd = 0.4 nM / Bmax = 120 fmol/mg
protein) and lower (Kd = 8.2 nM / Bmax = 432 fmol/mg protein) affinity binding components is observed both in
saturation binding experiments followed by Schatchard analysis, and in equilibrium competition binding studies. The
signs of receptor multiplicity, e.g., curvilinear Schatchard plots or biphasic displacement curves are seen only if the non-
specific binding is measured in the presence of excess unlabeled endomorphin-1 and not in the presence of excess
unlabeled naloxone. The second, lower affinity non-opioid binding site is not recognized by heterocyclic opioid alkaloid
ligands, neither agonists such as morphine, nor antagonists such as naloxone. On the contrary, endomorphin-1 is
displaced from its lower affinity, higher capacity binding site by several natural neuropeptides, including methionine-
enkephalin-Arg-Phe, nociceptin-orphanin FQ, angiotensin and FMRF-amide. This naloxone-insensitive, consequently
non-opioid binding site seems to be present in nervous tissues carrying low density or no µ-opioid receptors, such as
rodent cerebellum, or brain of µ-opioid receptor deficient (MOPr–/–) transgenic or 'knock-out' (K.O.) mice. The newly
described non-opioid binding component is not coupled to regulatory G-proteins, nor does it affect adenylyl cyclase
enzyme activity. Taken together endomorphin-1 carries opioid and, in addition to non-opioid functions that needs to be
taken into account when various effects of endomorphin-1 are evaluated in physiological or pathologic conditions.
K e y  w o r d s : tritiated endomorphin-1, naloxone insensitive site, µ-opioid peptide receptor, rat brain, radioligand binding,
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endomorphins stimulate Gi protein activation (10-13), inhibit
adenylyl cyclase (10, 11, 14) and induce agonist stimulated
receptor internalization (15, 16).
Despite all previous evidence on µ-receptor selectivity of
endomorphins some studies do not support the idea of exclusive
action of endomorphins through µ-receptors. Thus,
endomorphin-1 induced antinociception was not reversed by µ1-
receptor selective antagonist naloxonazine in mice (17), and
antagonists beta-funaltrexamine and naloxonazine were
ineffective in antagonizing endomorphin-1's antinociceptive
effect in diabetic mice (18). The experiments with endomorphin-
1 stimulated viral replication in microglial cell culture also
suggest that endomorphin-1 acts through 'atypical' µ-receptors
(19). Fischer and Undem (20) demonstrated that endomorphins
produced a concentration-dependent inhibition of the electrical
field stimulation-induced tachykinin-mediated contractions of the
guinea pig bronchus. Surprisingly, only endomorphin-1 effects
could be blocked by naloxone (10 µM), whereas endomorphin-2
effects were not affected by any opioid receptor-specific
antagonist. Endomorphins evoke different cardiorespiratory
effects of which ventilatory responses are probably non-opioid-
mediated, as they were not attenuated by opioid antagonists (21).
Tachykinin agonist and antagonist pepetides posses a wide
range of physiological functions from pain regulations to cancer
growing (22). Kosson et al. (23) showed weak but significant
receptor affinity of endomorphin-1 on NK1- (70 µM) and NK2-
(6.2 µM) receptors and endomorphin-2 for NK2- (72 µM)
receptors. Functional bioassays show weak tachykinin
antagonist properties of endomorphin-1 and -2. Although the
affinities of endomorphin-1 to NK2- and NK1- receptors are 6000
and 70,000 times lower than its affinity for the µ-receptor, this
'tachykinin component' may nonetheless play a significant
modulatory role of the major opioid agonist function of
endomorphin-1. Botros et al. (24) found that endomorphin-2
showed a comparatively high binding affinity (7.5 ± 0.7 nM) for
the SP1-7 substance P sites, whereas endomorphin-1 exhibited
weak binding (1030 ± 43 nM). This further supports that
endomorphin-2 in addition to its affinity for the µ-receptor also
may interact with a non-opioid site.
Therefore, we hypothesized that endomorphin-1 may bind to
more than one receptor/binding-sites. To study the binding of
endomorphins we generated tritiated endomorphin-1 and found
that [3H]endomorphin-1 has at least two clearly distinguishable
binding sites, one that appears to be a high affinity µ-receptor
site while the other site has a somewhat lower affinity but it is




TBq/mmol) was synthesized in our institute (25). Guanosine-5'-
[γ-35S]-triphosphate (1204 Ci/mmol) was purchased from the
Isotope Institute Ltd. (Budapest, Hungary). Naloxone was from
Endo Labs (Garden City, NJ, USA). Morphine and naltrindole
were from ICN-Hungary Co. (Tiszavasvari, Hungary).
Hemorphin was prepared as described in Szikra et al. (26).
Angiotensin IV-was from Sigma. Neuropeptide FF (NPFF) was a
kind gift from Laszlo Prokai (Department of Molecular Biology
and Immunology, University of North Texas, Health Science
Center at Fort Worth? Fort Worth, TX, USA). DAMGO [D-Ala2-
(N-Me)Phe4-Gly5-ol] Enkephalin, Nociceptin, Leu-enkephalin,
Met-enkephalin and β-endorphin were purchased from Bachem
(Bubendorf, Switzerland). AMPA, GABA, Glu, (–)MK801 and
()MK801 was from Tocris (Bristol, United Kingdom). SKF (–)
and SKF (+), ( ) and (+)N-allylnormetazocine (SKF-10,047) were
generous gifts from NIDA (Research Triangle Park, NC, USA).
Dextrorphan and levorphanol were purchased from Hoffmann-La
Roche (Nutley, NJ, USA). Bovine serum albumin (BSA) and
Coomassie Brilliant Blue G250 were from Serva Feinbiochemica
GmbH (Heidelberg, Germany). Ready Safe liquid scintillant was
purchased from Beckman (Fullertone, CA, USA).
Endomorphin-1, endomorphin-2, H-Tyr-Gly-Gly-Phe-Met-
Arg-Phe-OH (MERF) (27), and Ile5,6-deltorphin II (28),
dynorphin (1-11), FMRF, and TIPP (H-Tyr-Tic-Phe-Phe-OH)
(29) were prepared by solid phase peptide synthesis and purified
by high performance liquid chromatography in our institute.
All other chemicals used in this study were of analytical
grade and purchased from Sigma (St. Louis, USA) or
Reanal/Egis Pharmaceuticals (Budapest, Hungary).
Animals
Three days old and adult male albino Wistar rats with 250 –
280 g body weight (Human Rt., Godollo, Hungary) were used in
the study. They were housed in the local animal house of the
Biological Research Center (BRC, Szeged, Hungary). Rats were
kept in groups of six, allowed free access to food and water and
maintained on a standard 12-h light:12-h dark cycle (lights on
between 06:00 and 18:00 h) until the time of sacrifice. Animal
experiments were performed under the control of the following
declaratory statutes: the European Communities Council
Directives (2010/63/EU) and the Hungarian Act for the
Protection of Animals in Research (XXVIII.tv. 32.§).
Brains of µ-receptor knockout mice were kindly provided by
Professor Brigitte L. Kieffer (UPR 9050 CNRS, ESBS
Universite Louis Pasteur, 67400 Illkirch, Strasbourg, France).
The generation of µ-receptor deficient mice was described
previously (30).
Preparation of rat brain membranes
A crude membrane fraction was prepared from Wistar rat
forebrains according to a method of Pasternak with small
modifications (31, 32). The animals were decapitated, and the
brains without cerebella were rapidly removed, and washed
several times with chilled 50 mM Tris-HCl buffer (pH 7.4). The
brains were weighed and suspended in 5 (v/w) of brain tissue of
the ice-cold buffer. Tissues were homogenized by a Braun teflon-
glass homogenizer (10 – 15 strokes, 1000 rev./minute), and
filtered through four layers of gauze to remove large aggregates.
The volume of the suspension was supplemented to a final buffer
volume/membrane pellet ratio of 30 (ml/g). After centrifugation
with a Beckman J21M apparatus (40,000 × g, at 4°C, for 20 min,
JA20 rotor), the resulting pellet was resuspended in fresh buffer
(30 v/w) using a vortex. The suspension was incubated at 37°C for
30 min to remove any endogenous opioids. Centrifugation was
repeated under the same conditions as described above, and the
final pellet was resuspended in five volumes of 50 mM Tris-HCl
buffer (pH 7.4) containing 0.32 M sucrose to give a final protein
concentration of 3 – 4 mg/ml. Aliquots (5 ml) of the membrane
samples were frozen in liquid nitrogen and then stored at –80°C.
The protein concentration was determined by the Bradford
method (33) using bovine serum albumin as standard. Before use
the membranes were thawed and resuspended in 50 mM Tris-HCl
buffer (pH 7.4) and centrifuged (40,000 × g, at 4°C, for 20 min) to
remove sucrose and used immediately in binding assays.
Preparation of cerebellar homogenates
Following cervical dislocation, the brains were rapidly
removed. Cerebella were dissected and homogenized in 10
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volumes of an ice-cold homogenization buffer of the following
composition (in mM): TrisHCl pH 8.0, 10; EDTA, 2; DTT, 1;
PMSF, 0.5. Homogenates were aliquoted and stored at –80°C
until use.
Radioreceptor binding assay
Radioligand binding experiments were performed as
described (32). Briefly, the membrane suspensions from rat brain
(protein concentration of 0.3 – 0.5 mg/ml) were incubated in
glass tubes for 45 min at 24°C with the radioligand in a final
volume of 1 ml. Incubations were carried out in 50 mM Tris-HCl
buffer (pH 7.4). Incubation was started by the addition of
membrane suspension and terminated by rapid filtration through
Whatman GF/C glass fiber filters using a Brandel M24R Cell
Harvester. After three washings with 5 ml portions of ice-cold
buffer (50 mM Tris-HCl, pH 7.4) filters were dried for 3 hours
at 37°C. The radioactivity was measured in a toluene-based
scintillation cocktail, using a Wallac 1409 scintillation counter.
Experiments were carried out in duplicate and repeated several
times. Ligand binding data were evaluated by GraphPad Prism
4.0 (34), using a non-linear least-squares algorithm. Data are
generally expressed as arithmetic means ± S.E.M of at least three
repeated assays.
[35S]GTPγS binding experiments
Functional coupling of the activated receptors with the cell
membrane Gi/o-proteins was measured by [35S]GTPγS binding
assays. Rat brain membranes (containing ~10 µg of
protein/sample tube) were incubated for 60 min at 30°C in Tris-
EGTA buffer (50 mM Tris-HCl buffer, 3 mM MgCl2, 1 mM
EGTA, 100 nM NaCl, pH 7.4) containing 0.05 nM [35S]GTPγS
with increasing concentrations (10–9 10–5 M) of opioid ligands
tested in the presence of 30 µM GDP in a final volume of 1 ml.
For positive control 10–5 M DAMGO was used. Basal activity
taken as 100% specific binding was measured by subtracting the
non-specific binding (determined in the presence of 100 µM
unlabeled GTPγS) from the total binding (measured in the
absence of tested compounds). The incubation was started by the
addition of [35S]GTPγS and was terminated by rapid vacuum
filtration through Whatman GF/B glass fiber filters. Filters were
washed three times with ice-cold Tris-HCl buffer (50 mM, pH
7.4) and then dried. The bound radioactivity was measured in a
ready safe scintillation cocktail, using a Wallac 1409 liquid
scintillation spectrometer. G-protein stimulation is given as
percentage of the basal activity. Data were calculated from three
independent experiments performed in triplicates. Efficacy
(Emax) and potency (EC50) values Data were calculated by fitting
sigmoid dose-response curves using the GraphPad Prism 4.0
program (34).
Measurement of adenylyl cyclase activity
Adenylyl cyclase assay was performed on brain
homogenates of rat cerebellum and cortex. Brain homogenates
were pre-incubated with the agonists or with vehicle for 10 min
at room temperature. When used, antagonist was added 10 min
before adding an agonist. Reaction mixtures contained 15 – 40
µg protein, 50 mM Tris-HCl, 5 mM MgCl2, 10 µM GTP, 10 mM
cAMP (containing 20,000 cpm 3H-cAMP; Amersham, France), 1
mM ATP (containing 106 cpm [α-32P]-ATP; Amersham, France),
5 mM creatine phosphate and 250 µg/ml creatine kinase in a
total volume of 60 µl. After 10 min of incubation at 35°C,
reactions were stopped with 500 mM HCl then neutralized with
1.5 M imidazole. The assay mixture was then loaded on alumina
columns to separate cAMP from ATP. Column flow-through was
measured by liquid scintillation counting using two counting
windows for 3H and 32P, to determine the amount of [3H]cAMP
and [32P]cAMP, respectively. The formed [32P]cAMP amount
was then corrected for the recovery of the added [3H]cAMP. All
measurements were run in triplicates. Protein amount was
determined using the BioRad protein assay (BioRad, Germany).
Data were analysed with Prism 4.0 from GraphPad (34).
RESULTS
[3H]endomorphin-1 was prepared by dehalotritiation method
through [3’,5’ -diI-Tyr1]endomorphin-1, which was tritiated in
the presence of Pd/BaSO4. The final product had a specific
radioactivity of 2.35 TBq/mmol (25). The specific binding of
[3H]endomorphin-1 was temperature-dependent (data not
shown) and the highest specific binding was found to be at 24°C
using glass test tubes and C type of Whatmann glass fiber filter.
Addition of different enzyme inhibitors to experimental buffer
had no positive effect on specific binding; therefore, all the
following experiments were performed using 50 mM Tris buffer
(pH 7.4). Kinetic studies revealed that [3H]endomorphin-1
binding reaches the steady state level in 45 minutes of incubation
(data not shown). These conditions were used throughout the
following experiments.
Saturation binding experiments were carried out in rat brain
membranes at varying concentrations of the radiolabelled
endomorphin-1 (from 0.01 nM to 100 nM) and non-specific
binding was determined either in the presence of 10–5 M
naloxone (Fig. 1A, open circles) or 10–5 M unlabelled
endomorphin-1 (Fig. 1A, filled circles). Specific binding was
found to be saturable in both cases. Surprisingly, we found that
specific binding of [3H] endomorphin-1 with nonspecific
binding measured by unlabelled endomorphin-1 was
significantly higher than [3H]endomorphin-1's specific binding
with nonspecific binding determined in the presence of
unlabelled naloxone (Fig. 1A).
The equilibrium dissociation constant (Kd) and the maximal
number of binding sites (Bmax) were calculated by non-linear
regression analysis. The obtained results indicated the existence
of a single binding site when 10–5 M naloxone was used to
determine non-specific binding (Kd of 1.0 ± 0.1 nM and the Bmax
was 188.0 ± 21.7 fmol/mg protein). Linear regression analysis of
the data after Scatchard transformation confirmed the existence
of a single binding site with naloxone (Fig. 1B).
After determining the non-specific binding by using 10–5 M
endomorphin-1 the nonlinear regression analysis showed that
the best fit could be obtained by an equation modelling two
binding sites. The equilibrium dissociation constants were Kd1=
0.4 ± 0.1 nM and Kd2= 8.2 ± 1.4 nM and the corresponding Bmax
values were 119.6 ± 18.5 and 432.5 ± 83.7 fmol/mg protein,
respectively. The Scatchard transformation of the binding
isotherm was curvilinear, also suggesting the existence of two
classes of binding sites (Fig. 1C). Non-specific binding of
[3H]endomorphin-1 was under 30% of total binding at a
radioligand concentration of 0.4 nM which increased to 60% at
8.2 nM (data not shown). Both the high and low affinity binding
of [3H]endomorphin-1 to rat brain membranes were blocked by
heat treatment (50°C for 60 min at 8.5 nM [3H]endomorphin-1
radioligand concentration) (Fig. 2) or by N-ethyl-maleimide pre-
treatment or by α-chymotrypsin pre-treatment (data not shown)
suggesting that both the high and low affinity [3H]endomorphin-
1 binding sites are composed of proteins.
The existence of two binding sites for endomorphin-1 was
further confirmed by equilibrium homologous competition
experiments resulting in a biphasic curve (Fig. 3).
[3H]endomorphin-1 (0.4 nM) was displaced by endomorphin-1
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in a concentration dependent manner giving an interim plateau at
around 35% of total binding. This higher affinity binding had a
Kd value in the subnanomolar concentration range (Kd1 = 7.2 ±
3.0 pM). The remaining ~35% of [3H]endomorphin-1 binding
was displaced by a Kd value that was more than one order of
magnitude lower (Kd2 = 8.9 ± 1.5 nM). These higher and lower
affinity values were comparable to those obtained from
saturation binding experiments.
The high affinity endomorphin-1 binding (0.4 nM) was
displaced by MOP receptor ligands with high affinity (Ki in the
nanomolar range) and by DOP or KOP ligands with much lower
affinity (Table 1). The binding of endomorphin-1 to µ-receptor
was stereospecific, demonstrated by the displacement of
[3H]endomorphin-1 with levorphanol (Ki value of 0.31 ± 0.13
nM) and its pharmacologically inactive enantiomer dextrorphan
(Ki > 400 nM) (Table 1). The marked differences (three orders
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Fig. 1. Saturation binding curve and Scatchard plot of
[3H]endomorphin-1 binding.
(A) Summary of saturation binding isotherms for
[3H]endomorphin-1. (B) Scatchard plot of
[3H]endomorphin-1 binding, using 10–5 M naloxone to
determine non-specific binding. (C) Scatchard plot of
[3H]endomorphin-1 binding, using 10–5 M
endomorphin-1 to determine non-specific binding. Rat
brain membranes were incubated with increasing
concentration of [3H]endomorphin-1 in the presence
and absence of 10–5 M naloxone () or 10-5 M
endomorphin-1 () for 45 min at 24°C. Graphs depict
a representative experiment, carried out in duplicates
and repeated two times with similar results.
of magnitude) in the equilibrium inhibition constant values of
the stereoisomer compounds reflect stereoselective site
recognition (35). These features suggest that the high affinity
binding occurs on µ-receptors. The binding selectivity of
[3H]endomorphin-1 towards mu binding site was about 1000
fold higher than for delta site, and about 20 fold higher, than for
kappa binding site.
To determine the receptor specificity of the naloxone
insensitive low affinity binding site for endomorphin-1,
heterologous displacement experiments were carried out in the
presence of 8 nM [3H]endomorphin-1 and a wide range of opiate
and non-opioid receptor ligands at a fixed 10–5 M concentration
in the presence of 10–5 M naloxone (Fig. 4). Based on the data we
obtained the results can be categorized into several groups: i)
ligands that had no effects on [3H]endomorphin-1 binding in the
absence or presence of naloxone (these were some of the ligands
for glutamate, GABA, sigma, dopamine, nor-epinephrine and
serotonin receptors); ii) ligands that partially displaced
[3H]endomorphin-1 binding in the absence of naloxone to a lesser
extent than naloxone itself, but in the presence of naloxone they
had no effect on [3H]endomorphin-1 binding; iii) ligands that
displaced as much [3H]endomorphin-1 as naloxone, but in the
presence of naloxone they had no additional effect (DAMGO,
morphine, naltrindole or Ile 5,6deltorphin, SKF10,047(–)); iv)
ligands that were at least as potent as naloxone itself in displacing
[3H]endomorphin-1, and addition of naloxone produced further,
but not complete, [3H]endomorphin-1 displacement; v) ligands
that fully displaced [3H]endomorphin-1 binding, consequently
the addition of naloxone had no further effect, like: endomorphin-
1, endomorphin-2, β-endorphin, dynorphin(1-11), methionine-
enkephalin, nociceptin and MERF; vi) ligands that displaced only
35 – 40% [3H]endomorphin-1 binding themselves, however, in
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Fig. 2. Effect of heat denaturation on
[3H]endomorphin-1 binding. Rat brain
membranes were incubated for various time
intervals at 50°C with 8.5 nM [3H]endomorphin-
1 in the presence and absence of 10–5 M naloxone
(q) or 10–5 M endomorphin-1 (¢). Points
represent means ± S.E.M. of at least three
experiments, carried out in duplicates.
Fig. 3. Homologous displacement of
[3H]endomorphin-1 on rat brain membrane. Rat
brain membranes were incubated with 0.4 nM
[3H]endomorphin-1 for 45 min at 24°C in the
presence of increasing concentrations (10–16 – 10–5
M) of endomorphin-1. Data were analyzed by
both one-site and two-site competition models,
and they were compared with an F test to obtain
optimal fit. The curve represents the result of the
two site fits. Specific binding was determined by
subtracting the values obtained in the presence of
10-5 M endomorphin-1 from the total binding and
used for the normalization of the data as 100%.
Data points are the averages of at least 3
independent experiments in duplicates ± S.E.M.
the presence of naloxone, the [3H]endomorphin-1 binding was
fully displaced. Peptides in this last group (angiotensin IV,
FMRF-amide, NPFF) appear to bind exclusively to the naloxone
insensitive binding site of endomorphin-1.
Following the basic characterization of the high and low
affinity binding sites for [3H]endomorphin-1 in rat forebrain we
checked, whether the low affinity binding occurs in tissues that
have no or very few opioid receptors. Therefore, we prepared crude
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Selectivity Ligand Ki (nM) ± S.E.M. 
General opioid antagonist Naloxone     0.62 ± 0.07 
µ-receptor selective Endomorphin-1   1.00 ± 0.1 
 Endomorphin-2     2.23 ± 0.08 
 DAMGO     0.84 ± 0.06 
-receptor selective TIPP (Tyr-Tic-Phe-Phe)   739.33 ± 51.67 
 Ile
5,6
- Deltorphin-II 1110.67 ± 85.76 
κ-receptor selective  Dynorphin(1-17)   15.05 ± 3.73 
 MERF    20.06 ± 6.35 
Opioid agonist, active stereomer  Levorphanol     0.31 ± 0.13 
Opioid agonist, inactive stereomer Dextrorphan   481.67 ± 81.53 
Rat brain membranes were incubated for 45 min at 24°C with 0.4nM [3H]endomorphin-1 in the presence of increasing concentrations
of opioid ligands. Ki values were calculated by fitting displacement binding curves using Graphpad Prism 4.0 program non-linear least-
squares algorithm. Values represent the means ± S.E.M. of several independent experiments performed in duplicate.
Table 1. Potencies of various opioid ligands in inhibiting 0.4 nM [3H]endomorphin-1 binding to rat brain membranes.
Fig. 4. Displacement of 8 nM [3H]endomorphin-1 binding by different receptor specific ligands in the presence of 10–5M naloxone.
Heterologous displacement experiments were carried out in rat brain membranes incubated at 24°C for 45 min in the presence of 8
nM [3H]endomorphin-1 and a wide range of opiate and non-opiate receptor ligands at a fixed 10–5 M concentration in the absence or
presence of 10–5M naloxone. Values represent the means ± S.E.M. of three independent experiments performed in duplicate.
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1 in the presence and absence of
10–5 M endomorphin-1 () for 45
min at 24°C. Each value represents
the mean of a single experiment,
carried out in duplicates and
repeated two times with similar
results.
Fig. 6. Saturation binding isotherm for
[3H]endomorphin-1 in brains of µ-opioid receptor
KO mice. Brain membranes of µ-receptor KO
mice were incubated with increasing
concentration of [3H]endomorphin-1 in the
presence and absence of 10–5 M naloxone (¢) or
10-5 M endomorphin-1 (q) for 45 min at 24°C.
Each value represents the mean of a single
experiment, carried out in duplicates and repeated
two times with similar results.
Fig. 7. Saturation binding isotherms for
[3H]endomorphin-1 in p3 rat forebrain
membrane. P3 rat brain membranes were
incubated with increasing concentration of
[3H]endomorphin-1 in the presence and absence
of 10–5 M naloxone (¢) or 10–5 M endomorphin-
1 (q) for 45 min at 24°C. Each value represents
the mean of a single experiment, carried out in
duplicates and repeated three times with similar
results.
homogenates from rat cerebellum that has been shown to be mostly
free of µ-receptors (36, 37) and forebrain of µ-receptor K.O. mice
(30). As expected, no displacement of [3H]endomorphin-1 binding
was observed in the presence of naloxone despite the
[3H]endomorphin-1 binding to both membrane preparations (Figs.
5 and 6). The binding to rat brain cerebellar membrane was
saturable, and best fitted with the single binding site model, giving
a Kd of 18.2 ± 2.82 nM and a Bmax of 403 ± 48.6 fmol/mg (Fig. 5).
Similarly, in µ-receptor K.O. mouse brains the [3H]endomorphin-1
binding was saturable, fully independent of naloxone giving a Kd
of 14.5 ± 1.3 nM and a Bmax of 423.02 ± 79.5 fmol/mg (Fig. 6).
Scatchard transformation of both sets of data supported a single
binding site model (data not shown).
We tested extracts of three-day old p3 rat brains for
endomorphin-1 binding. Interestingly, we found that the
proportion of the non-opioid binding site is very high in brains
of p3 rats (85 – 90% of the total binding, Kd = 8.2 ± 2.4 nM; Bmax
= 841 ± 42 fmol/mg when endomorphin-1 was used for non-
specific binding, Kd = 1.2 ± 0.2 nM; Bmax = 127 ± 17 fmol/mg
when naloxone was used for non-specific binding.), suggesting
that this low affinity, non-opioid [3H]endomorphin-1 binding site
is present in rodent brain from an early age (Fig. 7).
Next we examined whether the signalling pathway activated
by µ-receptor is modulated by the low affinity, naloxone
insensitive endomorphin-1 binding site. The stimulation of GTP-
binding and the inhibition of adenylyl cyclase activity were
measured in rat cortical and compared to cerebellar membranes
that served as a negative control. Endomorphin-1 produced a
60% increase in [35S]GTPγS binding and a 15% decrease in
adenylyl cyclase activity in rat cortical membranes compared to
basal values (Fig. 8A and 8B). However, both of these changes
were fully reversed by the addition of 10–5 M naloxone. In
addition, endomorphin-1 did not affect [35S]GTPγS binding and
adenylyl cyclase activity in membranes prepared from rat
cerebellum. These results suggest that the naloxone insensitive
binding does not contribute to the classical µ-receptor mediated
signalling events.
DISCUSSION
The discovery of endomorphin-1 and -2 by Zadina et al. (7)
was a major breakthrough in opioid research. These two peptides
are thought to be natural ligands for the µ-opioid receptors. In
spite of the vigorous research for about three decades after the
description of the endogenous ligands for the δ- and κ-receptors
(enkephalins and dynorphins) (2, 5), there was no acceptable
candidate for the µ-receptors. Opioid receptors participate a wide
range of physiological functions incuding pain regulations (38)
and gastrointestinal transit ( 39). Endogenous opioid peptides are
as good painkillers as opiate alkaloids, although systematically
given peptides have to be protected against rapid inactivation by
peptidase enzymes. A highly potent inhibitor of such peptide
degrading enzymes has recently been introduced (40).
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Fig. 8. Effects of endomorphin-1 on signaling.
(A) Stimulation of [35S]GTPγS binding by
endomorphin-1 in rat forebrain- and cerebellar
homogenates. Endomorphin-1 (10–5 M) was
incubated in the presence or in the absence of
opioid antagonists naloxone (10–5 M) for 60
min at 30°C as described in Materials and
methods. Dark bars represent rat forebrain and
light bars represent rat cerebellar samples. Data
represent means ± S.E.M. of three to four
independent experiments, each performed in
triplicate. (B) Inhibition of adenylyl cyclase
activity by endomorphin-1 in rat forebrain- and
cerebellum, in the presence and absence of
naloxone. Adenylyl cyclase activity was
measured in rat forebrain- and cerebellar
homogenates in the presence endomorphin-1
(10–5 M) or endomorphin-1 (10–5 M) + naloxone
(10–5 M). Basal activity (100%) refers to the
amount of cAMP generated in the absence of
opioid agonist. Data are means ± S.E.M. values
from three independent experiments, each
performed in triplicate.
Since the discovery of the endomorphins in 1997, several
studies were undertaken for a detailed pharmacological
characterization of these compounds (41, 42). Endomorphin-1
and 2 was prepared in tritiated form (25, 43) for a more complete
characterization of these peptides (10, 11).
In the present paper we report a comprehensive study
including binding properties of [3H]endomorphin-1 and found
that endomorphin-1 has at least two clearly distinguishable
binding sites, one that appears to be the µ-receptor site while the
other site has a somewhat lower affinity but it is fully
independent of µ-opioid receptors. Non-opioid effects have
already been described for other opioid peptides (for review see
27). Therefore it is not unprecedented that endomorphins can
also bind to non-opioid binding sites. There is plenty of evidence
suggest that this can happen, as endomorphins had been shown
to be involved in µ-receptor independent antinociception (17,
18), viral replication (19), tachykinin-mediated contractions of
the guinea pig bronchus (20), excitatory ventilatory responses
(21), binding to the neurokinin receptors (23) as demonstrated
by subtance P (1-7) fragment (24). It also seems that the
endomorphin-2 binding to the substance P fragment site could be
blocked by naloxone (24).
In radioligand binding assays (RBA) the level of non-specific
binding has to be determined in the presence of excess (around
thousand fold concentration) unlabelled receptor ligand.
Generally two types of such measurements exist: the non-specific
agent is chemically same as the radioligand (homologous
competition, e.g., nanomolar [3H]endomorphin-1 versus
micromolar unlabelled endomorphin-1); the chemical structure of
the radioprobe and the non-specific ligand is different
(heterologous competition, e.g., nanomolar [3H]endomorphin-1
versus micromolar unlabelled naloxone). In theory both method
helps in determining specific ligand binding giving the same or
very similar numeric values. However, in our practice naloxone
and endomorphin-1 gave rather different results in calculating the
level of non-specific binding. Naloxone produced monophasic
competition curves (not shown), while using endomorphin-1 as
non-specific compound clearly biphasic displacement curves
composed of higher and lower affinity binding components were
obtained (Fig. 3). The higher affinity portion corresponds to the
µ-opioid receptor binding site, which is a typical GPCR
recognition site, whereas the remaining binding component
represent a neuropeptide-sensitive (enkephalin, nociceptin,
NPFF, FMRF-amide, etc. accessible, see Fig. 4) additional non-
opioid binding site. The exact nature of the non-opioid site needs
to be determined. This observation of non-opioid binding sites
does not stand alone in the literature. Benyhe et al. (32) described
very similar binding profile for the heptapeptide enkephalin
(Met-enkephalin-Arg-Phe, MERF) peptide pair [3H]MERF
versus unlabelled MERF in rat brain membranes. The non-opioid
binding site for [3H]MERF was further characterised in cerebellar
membranes of guinea-pig and rat (35) and suggested to be
associated with the sigma2 binding or receptor site. A very
similar non-opioid recognition site was described for the
hemoglobin originated heptapeptide VV-hemorphin-7 in rat brain
membranes (26). The significance of the non-opioid binding sites
and non-opiate effects of a number of endogenous opioid
peptides was described by Wollemann and Benyhe (27).
Saturation binding experiments were carried out on rat brain
membranes. The obtained results indicated the existence of a single
binding site when 10–5 M naloxone was used to determine non-
specific binding (Kd of 1.0 ± 0.1 nM and the Bmax was 188.0 ± 21.7
fmol/mg protein). Linear regression analysis of the data after
Scatchard transformation confirmed the existence of a single
binding site with naloxone (Fig. 1B). After determining the non-
specific binding by using 10–5 M endomorphin-1 the nonlinear
regression analysis showed that the best fit could be obtained by an
equation modelling two binding sites. The equilibrium dissociation
constants were Kd1 = 0.4 ± 0.1 nM and Kd2 = 8.2 ± 1.4 nM and the
corresponding Bmax values were 119.6 ± 18.5 and 432.5 ± 83.7
fmol/mg protein, respectively. Analysis of the data after Scatchard
transformation confirmed that there are two binding sites for
endomorphin-1 on rat brain membranes (Fig. 1C).
The obtained Bmax value for the high affinity binding of
[3H]endomorphin-1 was in agreement with the values reported
for µ-receptor density for other µ-receptor selective peptide
radioligands, such as [3H]endomorphin-2 (10), [3H]TAPP (40),
[3H]PL-017 (41), and [3H]dermorphin (46).
It is important to note that the endomorphin-1 binding
appears to be associated with proteins and are not the result of a
nonspecific chemical binding as both the high and low affinity
bindings were abolished by heat or (Fig. 2) or N-ethyl-maleimide
and alpha-chymotrypsin (data not shown) pre-treatment.
In the homologous competition experiments (Fig. 3)
[3H]endomorphin-1 (0.4 nM) was displaced by endomorphin-1 in
a concentration dependent manner giving an interim plateau at
around 35% of total binding. This high affinity binding had a (Kd1
= 7.2 ± 3.0 pM), the remaining ~35% of [3H]endomorphin-1
binding was displaced by a Kd2 = 8.9 ± 1.5 nM. The existence of
two binding sites for endomorphin-1 was further confirmed by
these homologous displacement experiments. These high and low
affinity values were comparable to those obtained from saturation
binding experiments. The high affinity endomorphin-1 (0.4 nM)
binding was stereospecific as found by displacements of
[3H]endomorphin-1 with the biologically potent opioid
levorphanol (Ki value of 0.31 ± 0.13 nM) and its
pharmacologically inactive enantiomer dextrorphan (Ki > 400
nM) (Table 1). The high affinity endomorphin-1 binding (0.4 nM)
was displaced by µ-receptor ligands with high affinity (Ki in the
nanomolar range) and by δ-receptor or κ-receptor ligands with
much lower affinity (Table 1). These features suggest that the
high affinity binding occurs on the µ-receptors.
Equilibrium binding of [3H]endomorphin-1 was further
studied in tissues not expressing opioid receptors. The binding to
rat brain cerebellar membrane was saturable, and best fitted with
the single binding site model, giving a Kd of 18.2 ± 2.82 nM and
a Bmax of 403 ± 48.6 fmol/mg (Fig. 4). Similarly, in µ-opioid
receptor KO mice brain (Fig. 5) the [3H]endomorphin-1 binding
was saturable, naloxone insensitive with a Kd of 14.5 ± 1.3 nM
and a Bmax of 423.02 ± 79.5 fmol/mg.
It has been shown that brains from newborn rats contain very
low levels of µ-receptor (47). Accordingly, we found that the
proportion of the non-opioid binding site is very high in 3 days
old rats (85 – 90% of the total binding, Kd = 8.2 ± 2.4 nM; Bmax
841 ± 42 fmol/mg when endomorphin-1 was used for non-
speceific binding, Kd = 1.2 ± 0.2 nM; Bmax = 127 ± 17 fmol/mg
when naloxone was used for non-speceific binding.), suggesting
that this low affinity, non-opioid [3H]endomorphin-1 binding site
is present in brain from an early age (Fig. 6).
Functional assays were performed on rat cortical- and
cerebellar membranes. Endomorphin-1 produced 60% increase
in [35S]GTPγS binding and a 15% decrease in AC activity in rat
cortical membranes compared to basal values (Fig. 7A and 7B).
The maximal inhibition values for the inhibition of adenylyl
cyclase were almost identical to that of morphine (10) and they
are in good agreement with those reported in the literature (48).
However, both of these changes were fully reversed by the
addition of 10–5 M naloxone. In addition, endomorphin-1 did not
affect AC activity and GTP binding in membranes prepared from
rat cerebellum. These results suggest that the naloxone
insensitive binding does not contribute to the classical µ-opioid
receptor mediated signalling events.
Experiments with truncated µ-opioid receptors showed that
endomorphin-1 binds to µ-receptor in different manner than other
613
µ-receptor specific ligands as morphine or DAMGO, or than the
non-selective opioid agonist naloxone (49). Competition binding
experiments of radio iodinated endomorphin-1 in mouse brain
with some endogenous opioid peptides as well as non-peptide
opioid ligands (50) demonstrated shallow competition curves
with the Hill coefficients far less than unity, suggesting the
existence of more than one class of binding sites.
Binding site heterogeneity is well established for the opioid
receptors. Early studies showed the presence of high affinity
binding component in different membrane preparations (51). This
might be the results of allosteric modulation, e.g., by sodium ions.
The idea of sodium ions altering G-protein-coupled receptor
(GPCR) ligand binding and signaling was first suggested for
opioid receptors in the 1970s and subsequently extended to other
GPCRs. Whether sodium accesses different receptor subtypes
from the extra- or intracellular sides, following similar or different
pathways, is still an open question. Earlier experiments in brain
homogenates suggested a differential sodium regulation of ligand
binding to the three major opioid receptor subtypes, in spite of
their high degree of sequence similarity (52). Another reason for
the binding heterogeneity might be the different affinities of G-
protein coupled and uncoupled receptors. Multiple affinity states
and guanyl-nucleotide (GppNHp) sensitivity of the radioligand
binding were reported in NG-108,15 neuroblastoma-glioma
hybrid cell membranes (53). It was also demonstrated that rates of
dissociation of [3H-D-Ala2-D-Leu5]enkephalin from bovine
hippocampal synaptic plasma membranes varied depending upon
association time, suggesting a multistep binding process. A slowly
formed high affinity state appeared to be rapidly converted to a
lower affinity state by the addition of GppNHp (54). The presence
of naloxone-insensitive binding sites for certain opioid peptides
was reported e.g., by Benyhe et al. (32) and extensively reviewed
by Wollemann and Benyhe (27). The naloxone insensitive site is
accessible for a number of endogenous peptide ligands (as shown
in Fig. 4), while many synthetic ligands and alkaloid compounds
are not able to interact with such binding site. Last but not least
receptor homo- and hetero-oligomerization might be a further
reason of having multiple binding sites. One mechanism for such
findings was the generation of novel signaling complexes by
receptor hetero-oligomerization, which resulted in significantly
different pharmacology for mu- and delta-receptor hetero-
oligomers compared with the individual receptors (55). Hetero-
dimerization of µ-receptors may not only be studied in
heterologous expression systems, but can directly be visualized in
living cells (56).
Thus, naloxone insensitive portion of endomorphin-1 binding
could be displaced by endogenous peptides with different
specificity, as well as synthetic delta compound TIPP, which has
strong structural resemblance to endomorphin-1. These
experiments proved the existence non-opioid binding of
endomorphin-1 in rodent brain. Overall the main conclusion of
this work is that we proved the presence of a non-opioid binding
site for endomorphins that appears to be responsible for all the
physiological actions that had been unrelated to an action through
µ-receptor. How these will benefit treatment strategies in the
future will require further investigations. However these results
highlight the importance for further research on uncovering the
whole spectrum of effects of these endogenous peptides.
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